Word: marketed
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
Today health care in general and obesity treatment in particular attract charlatans. You made little mention of the health risks of their schemes. Entrepreneurs who market diets via their books are promoting not health but self-image. Your report gave my patients permission to eat whatever they choose with utter disregard for their health. CLARENCE M. LEARY, M.D. Lodi, Calif...
...been an eager supporter of a new outfit that started in midyear, the Republican Attorneys General Association. Housed within the R.N.C., the group will develop policies with G.O.P. principles and support Republican A.G. candidates, says chairman Charlie Condon, attorney general of South Carolina. Among those principles: letting the free market be free. Condon, the only state attorney general to drop off the Microsoft case, won't say how much the company donated to the group. But he isn't embarrassed about the money--or about the $3,500 he solicited and got from Microsoft for his own election coffer after...
...Gore doesn't mince words when it comes to pushing for cheaper prescription drugs. So it makes sense that he opposes efforts by pharmaceuticals companies to extend their patent rights in order to block cheaper generic drugs from reaching the market...
...course, Schering-Plough would pay almost any amount of money to protect its exclusive right to sell Claritin, a drug that brings it more than $5 million in revenue a day. Claritin sales totaled $1.9 billion last year, and will balloon to $4 billion by 2002, according to a market analyst. To keep the money coming in, the company doubled its lobbying outlay starting in 1996 to more than $4 million in 1998. Among its other paid advocates: former Senator Dennis DeConcini; former Watergate assistant special prosecutor Richard Ben-Veniste; and Thomas Parry, former chief of staff for Senator Orrin...
...bill. Knight says he is closing down his firm to spend more time on the Gore campaign. But Schering-Plough is expected to continue the battle next year. If it loses again, the company has that contingency covered too: the FDA is currently considering its new super-Claritin for market approval. Its patent wouldn't expire until...